Intravenous pharmacokinetics, local tolerability, and hemolysis of an SBE7‐β‐cyclodextrin formulation of the neurokinin‐1 receptor antagonist vestipitant

Publisher： John Wiley & Sons Inc

E-ISSN： 2160-7648|4|2|130-136

ISSN： 2160-763X

Source： Clinical Pharmacology In Drug Development, Vol.4, Iss.2, 2015-03, pp. : 130-136

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist

By Giersbergen Paul   Dingemanse Jasper  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 2, 2007-02 ,pp. : 151-158

Springer Publishing Company

Access to resources Recommend Favorite

The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy

By Warr David  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 12, 2006-08 ,pp. : 1653-1658

Informa Healthcare

Access to resources Recommend Favorite

Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting

By Van Belle Simon JP   Cocquyt Veronique  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 18, 2008-12 ,pp. : 3261-3270

Informa Healthcare

Access to resources Recommend Favorite

LY 686017, a selective neurokinin 1 receptor antagonist, has demonstrated potential for alcoholism.

By  

Inpharma, Vol. 1, Iss. 1636, 2008-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting

By Navari Rudolph M  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 12, 2007-12 ,pp. : 1977-1985

Informa Healthcare

Access to resources Recommend Favorite